DSRV.io · Enforcement-informed quality intelligence
DSRVDSRV.io
Browse by regulation5 articles · 2 high · 2 moderate · 1 low

ICH Q9(R1)

Every DSRV article whose Regulatory Snapshot cites ICH Q9(R1): the enforcement case behind it, the inspection exposure it created, and what the desk would do about it.

Inspection exposure across the set
In brief
What has FDA cited under ICH Q9(R1)?
5 DSRV articles cite ICH Q9(R1). Enforcement cases behind them: FDA final Level 2 guidance, ICH Q8, Q9, and Q10 Questions and Answers (R5), adopted May 29, 2026 under docket FDA-2017-D-6821; Risk-proportionate control expectations under ICH Q9(R1) and pharmaceutical quality system principles in ICH Q10, applied to AI-assisted quality work; Data-integrity (ALCOA+) and quality risk management expectations under 21 CFR Parts 210/211 and ICH Q9(R1), applied to AI-generated inputs; FDA Warning Letter 320-26-53 to Microbiological Testing & Consulting, LLC, March 16, 2026, and FDA Warning Letter 320-26-54 to Yangzhou H&R Plastic Daily Chemical Co., Ltd., March 18, 2026; ICH Q9(R1) Quality Risk Management (revised 2023); recurring FDA 483 cleaning-validation observations. Inspection exposure across them: 2 high, 2 moderate, 1 low.
What does DSRV recommend for ICH Q9(R1)?
From the newest article (ICH Q8/Q9/Q10 R5 Just Raised the Floor on Risk Documentation): The decisive question is no longer whether a risk assessment was completed but whether its criteria, thresholds, and acceptability logic are explicit enough in the record to be defended without the author in the room. DSRV's matching service is the Quality Risk Management Tune-up, delivered through controlled intake at /submit. DSRV is decision support, not legal advice; verify against the official source each article names.
  1. 4 min readModerate exposure

    ICH Q8/Q9/Q10 R5 Just Raised the Floor on Risk Documentation

    FDA adopted ICH Q8/Q9/Q10 R5 as final Level 2 guidance on May 29, 2026. The alignment with Q9(R1) is the change that matters most for quality systems that still rely on informal risk judgments.

    Case
    FDA final Level 2 guidance, ICH Q8, Q9, and Q10 Questions and Answers (R5), adopted May 29, 2026 under docket FDA-2017-D-6821.
    DSRV take
    The decisive question is no longer whether a risk assessment was completed but whether its criteria, thresholds, and acceptability logic are explicit enough in the record to be defended without the author in the room.
  2. 7 min readLow exposure

    Where AI Can Safely Support Pharma Quality Teams

    AI is most valuable in regulated quality work when it supports human judgment rather than replacing it. We map the tasks where AI adds real, low-risk leverage — and where the human must stay in control.

    Case
    Risk-proportionate control expectations under ICH Q9(R1) and pharmaceutical quality system principles in ICH Q10, applied to AI-assisted quality work.
    DSRV take
    AI belongs in preparation, pattern-surfacing, and pressure-testing - leverage for the quality team, with every regulated conclusion handed back to an accountable human.
  3. 7 min readModerate exposurecited as a tag

    Why Generic AI Is Risky for Regulated Quality Decisions

    General-purpose AI tools can sound authoritative while being wrong in ways that matter under GMP. We explain the specific failure modes — and what regulated quality work requires instead.

    Case
    Data-integrity (ALCOA+) and quality risk management expectations under 21 CFR Parts 210/211 and ICH Q9(R1), applied to AI-generated inputs.
    DSRV take
    Plausibility is not the GMP bar - an AI input that cannot show its sources, and may invent them, cannot underwrite a regulated decision.
  4. 5 min readHigh exposurecited as a tag

    Contract Testing Labs Keep Exposing GMP Control Gaps

    Two March 2026 FDA-linked signals point to the same problem: contract testing oversight is still being treated as a paperwork exercise instead of a release-critical control. Small quality teams should read these cases as a warning about supplier qualification, data trust, and batch disposition risk.

    Case
    FDA Warning Letter 320-26-53 to Microbiological Testing & Consulting, LLC, March 16, 2026, and FDA Warning Letter 320-26-54 to Yangzhou H&R Plastic Daily Chemical Co., Ltd., March 18, 2026.
    DSRV take
    The control that matters is live oversight tiered by consequence: a lab generating release-critical data needs current evidence of reliability - recent oversight, meaningful performance review, clear escalation history - not an approved-vendor status that outlived the reality it describes.
  5. 11 min readHigh exposurecited as a tag

    Risk-Based Cleaning Validation: Applying ICH Q9 Principles in Practice

    Cleaning validation remains one of the most inspection-cited areas in pharmaceutical manufacturing. This article explores how a risk-based framework under ICH Q9 Rev.1 can rationalise your validation strategy.

    Case
    ICH Q9(R1) Quality Risk Management (revised 2023); recurring FDA 483 cleaning-validation observations.
    DSRV take
    A risk-based cleaning program is defensible only when worst-case selection and acceptance limits trace back to a documented risk assessment.
Address this risk

Quality Risk Management Tune-up

Bring the document that has to hold up under ICH Q9(R1). DSRV maps the evidence, names the gaps, and routes judgment calls to human review. Controlled intake, no public file upload.

Apply for the Stability Pilot Ask The Vault about ICH Q9(R1)

Regulatory intelligence and interpretation, not legal advice. Verify against the official FDA or ICH source each article names.